Modulation of Plasma Sphingosine-1-phosphate Levels via Dietary Salt Intervention in Chinese Adults: An Intervention Trial

Background: Salt is a crucial factor for blood pressure modulation, especially in salt-sensitive individuals. Sphingosine-1-phosphate (S1P), a pleiotropic bioactive sphingolipid metabolite participating in blood pressure regulation, has recently been identified as a novel lipid diuretic factor. However, the relationships among salt intake, circulating S1P levels, and blood pressure changes in human beings are unknown. Thus, we conducted this intervention trial to explore the effect of dietary salt intake on plasma S1P levels and to examine the relationship between S1P and blood pressure in Chinese adults.Methods: 42 participants (aged 18–65 years) were recruited from a rural community in Shaanxi, China. All participants first maintained their normal diet for 3 days, then sequentially ate a low-sodium diet (3.0 g/day NaCl) for 7 days, followed by a high-sodium diet (18.0 g/day NaCl) for 7 days. We assessed their plasma S1P concentrations on the last day of each intervention phase by liquid chromatography-tandem mass spectrometry. We classified the subjects who demonstrated at least a 10% increase in mean arterial pressure upon transitioning from a low-salt to a high-salt diet as salt-sensitive and the others as salt-resistant. Differences in repeated measures were analyzed by repeated-measures analysis of variance. Results: Plasma S1P levels decreased significantly from the baseline to low-salt diet period and increased from the low-salt to high-salt diet period. We observed this response in both salt-sensitive and salt-resistant individuals. Plasma S1P levels positively correlated with 24-hour urinary sodium excretion, but not 24-hour urinary potassium excretion. In line with plasma S1P level responses to salt intervention, systolic blood pressure (SBP) and mean arterial pressure (MAP) decreased from the baseline to low-salt diet period and increased from the low-salt to high-salt period. SBP positively correlated with plasma S1P and the correlation was stronger in salt-sensitive individuals than that in salt-resistant individuals. Conclusion: Low-salt dietary intervention decreases plasma S1P levels, whereas high-salt intervention reverses this change and S1P levels positively correlated with SBP in Chinese adults. This provides a high-efficiency and low-cost intervention for plasma S1P levels modulation, with implications for salt-induced blood pressure modulation. Trial registration: NCT02915315. Registered 27 September 2016, http://www.clinicaltrials.gov

[1]  Hong Liu,et al.  Inverse Correlation Between Plasma Sphingosine-1-Phosphate and Ceramide Concentrations in Septic Patients and Their Utility in Predicting Mortality , 2019, Shock.

[2]  J. Mu,et al.  An expert recommendation on salt intake and blood pressure management in Chinese patients with hypertension: A statement of the Chinese Medical Association Hypertension Professional Committee , 2019, Journal of clinical hypertension.

[3]  M. Ballantyne,et al.  Requirement for sphingosine kinase 1 in mediating phase 1 of the hypotensive response to anandamide in the anaesthetised mouse , 2019, European journal of pharmacology.

[4]  I. Kanazawa,et al.  Visceral fat accumulation is associated with increased plasma sphingosine-1-phosphate levels in type 2 diabetes mellitus. , 2018, Diabetes research and clinical practice.

[5]  G. Lip,et al.  2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[6]  S. Mousa,et al.  High Plasma Sphingosine 1-phosphate Levels Predict Osteoporotic Fractures in Postmenopausal Women: The Center of Excellence for Osteoporosis Research Study , 2018, Journal of bone metabolism.

[7]  D. Lyon,et al.  Paradoxical Association of Postoperative Plasma Sphingosine-1-Phosphate with Breast Cancer Aggressiveness and Chemotherapy , 2017, Mediators of inflammation.

[8]  A. Planas,et al.  Sphingosine-1-phosphate signalling—a key player in the pathogenesis of Angiotensin II-induced hypertension , 2017, Cardiovascular research.

[9]  Rachel K. Johnson,et al.  Recommended Dietary Pattern to Achieve Adherence to the American Heart Association/American College of Cardiology (AHA/ACC) Guidelines: A Scientific Statement From the American Heart Association , 2016, Circulation.

[10]  N. Cook,et al.  Salt Sensitivity of Blood Pressure: A Scientific Statement From the American Heart Association. , 2016, Hypertension.

[11]  E. Gao,et al.  Sphingosine 1-phosphate signaling contributes to cardiac inflammation, dysfunction, and remodeling following myocardial infarction. , 2016, American Journal of Physiology. Heart and Circulatory Physiology.

[12]  E. Schwedhelm,et al.  Decreased serum concentrations of sphingosine-1-phosphate in sepsis , 2015, Critical Care.

[13]  T. Hla,et al.  Nogo-B regulates endothelial sphingolipid homeostasis to control vascular function and blood pressure , 2015, Nature Medicine.

[14]  J. Jeppesen,et al.  Network-based analysis of the sphingolipid metabolism in hypertension , 2015, Front. Genet..

[15]  J. Garcia,et al.  The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension. , 2014, American journal of respiratory and critical care medicine.

[16]  Y. Alsancak,et al.  The Relationship between Pre-Infarction Angina and Serum Sphingosine-1-Phosphate Levels. , 2014, Acta Cardiologica Sinica.

[17]  S. Yusuf,et al.  Association of urinary sodium and potassium excretion with blood pressure. , 2014, The New England journal of medicine.

[18]  D. Hemmings,et al.  Review: novel insights into the regulation of vascular tone by sphingosine 1-phosphate. , 2014, Placenta.

[19]  A. Lisowska,et al.  Sustained decrease in plasma sphingosine-1-phosphate concentration and its accumulation in blood cells in acute myocardial infarction. , 2013, Prostaglandins & other lipid mediators.

[20]  S. Milstien,et al.  Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond , 2013, Nature Reviews Drug Discovery.

[21]  S. Ünlü,et al.  The relationship between preinfarction angina and serum sphingosine 1 phosphate levels , 2013 .

[22]  R. Fryer,et al.  The Clinically-tested S1P Receptor Agonists, FTY720 and BAF312, Demonstrate Subtype-Specific Bradycardia (S1P1) and Hypertension (S1P3) in Rat , 2012, PloS one.

[23]  S. Peters,et al.  FTY720 (fingolimod) increases vascular tone and blood pressure in spontaneously hypertensive rats via inhibition of sphingosine kinase , 2012, British journal of pharmacology.

[24]  J. Cyster,et al.  Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. , 2012, Annual review of immunology.

[25]  T. Hla,et al.  Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors. , 2011, Chemical reviews.

[26]  M. Tölle,et al.  Pharmacological relevance and potential of sphingosine 1‐phosphate in the vascular system , 2011, British journal of pharmacology.

[27]  T. Jørgensen,et al.  Genetics of the ceramide/sphingosine-1-phosphate rheostat in blood pressure regulation and hypertension , 2011, BMC Genetics.

[28]  Pin-Lan Li,et al.  A novel lipid natriuretic factor in the renal medulla: sphingosine-1-phosphate. , 2011, American journal of physiology. Renal physiology.

[29]  J. Kroetsch,et al.  Sphingosine-1-Phosphate–Dependent Activation of p38 MAPK Maintains Elevated Peripheral Resistance in Heart Failure Through Increased Myogenic Vasoconstriction , 2010, Circulation research.

[30]  T. Michel,et al.  Sphingosine-1-phosphate and modulation of vascular tone. , 2009, Cardiovascular research.

[31]  E. Ritz,et al.  Salt and its effect on blood pressure and target organ damage: new pieces in an old puzzle. , 2009, Journal of nephrology.

[32]  Y. Okamoto,et al.  Sphingosine-1-phosphate signaling and biological activities in the cardiovascular system. , 2008, Biochimica et biophysica acta.

[33]  M. Gaasenbeek,et al.  Candidate Genes That Determine Response to Salt in the Stroke-Prone Spontaneously Hypertensive Rat: Congenic Analysis , 2007, Hypertension.

[34]  J. Omens,et al.  Sphingosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. , 2007, American journal of physiology. Heart and circulatory physiology.

[35]  R. Proia,et al.  Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes , 2004, Journal of Pharmacology and Experimental Therapeutics.

[36]  T. Hla,et al.  Signaling of sphingosine-1-phosphate via the S1P/EDG-family of G-protein-coupled receptors. , 2002, Biochimica et biophysica acta.

[37]  D. Mazurais,et al.  Cell Type-specific Localization of Human Cardiac S1P Receptors , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[38]  M. Weinberger,et al.  Salt sensitivity of blood pressure in humans. , 1996, Hypertension.

[39]  Thomas Kahan,et al.  [2018 ESC/ESH Guidelines for the management of arterial hypertension]. , 2019, Kardiologia polska.

[40]  Xian-cheng Jiang,et al.  Sphingolipid metabolism and atherosclerosis. , 2013, Handbook of experimental pharmacology.

[41]  L. Mazzolai,et al.  Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease. , 2010, European heart journal.